Publication Beamlines Strategic Pillar
(2013). Fc VARIATIONS AND METHODS FOR PRODUCTION. Patent Number: AR085138A1.
(2013). ANTIBODY POLYPEPTIDES ANTAGONIZING CD40. Patent Number: AR086360A1.
(2018). Antibodies to the bradykinin b1 receptor. Patent Number: IL234830B.
(2022). Surgical method for treatment of auditory disease or condition. Patent Number: GB202213060D0.
(2025). ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING BCMA AND CD3 AND THEIR USES. Patent Number: FR23C1012I2.
(2023). Antibodies to tigit. Patent Number: IL298111A.
(2023). ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND USES THEREOF. Patent Number: CY2023007I2.
(2023). teclistamab. Patent Number: NL301219I2.
(2023). ANTI-BCMA ANTIBODIES, BCMA AND CD3-BINDING BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF. Patent Number: FR23C1011I1.
(2022). Nanoparticle platform for antibody and vaccine delivery. Patent Number: PT3661968T.
(2021). MODELING TEST. Patent Number: PT3311169T.
(2014). ANTIBODIES AGAINST BRADICININE B1 RECEIVER LIGANDS. Patent Number: AR090352A1.
(2018). Anti-hemagglutinin antibodies and methods of use. Patent Number: IL263320A.
(2023). Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof. Patent Number: IL257468B2.
(2017). ANTI-BCMA ANTIBODIES (CELL MATURATION ANTIGEN B), BINDING SPECIFIC MOLECULES THAT JOIN BCMA AND CD3 (AGGREGATE DETERMINANT 3), AND USES OF THESE. Patent Number: AR105724A1.